


## CLAIMS

1. A prostaglandin derivative represented by Formula (I):



wherein X is a halogen atom in the  $\alpha$ - or  $\beta$ -position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula:  $O(CH_2)_n$ ,

$S(O)_p(CH_2)_n$ ,

$O(CH_2)_qO(CH_2)_r$ ,

$O(CH_2)_qS(O)_p(CH_2)_r$ ,

$S(O)_p(CH_2)_qS(O)_p(CH_2)_r$  or

$S(O)_p(CH_2)_qO(CH_2)_r$

(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1),

$R^1$  is a  $C_{3-10}$  cycloalkyl group, a  $C_{1-4}$  alkyl- $C_{3-10}$  cycloalkyl group, a  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl group, [a  $C_{5-10}$  alkyl group, a  $C_{5-10}$  alkenyl group, a  $C_{5-10}$  alkynyl group or a bridged cyclic hydrocarbon group,

$R^2$  is a hydrogen atom, a  $C_{1-10}$  alkyl group or a  $C_{3-10}$  cycloalkyl group, and

m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. The prostaglandin derivative of Formula (I) according




to Claim 1 wherein  $R^1$  is a  $C_{3-10}$  cycloalkyl group, a  $C_{1-4}$  alkyl- $C_{3-10}$  cycloalkyl group, a  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl group, a branched  $C_{5-10}$  alkyl group, a branched  $C_{5-10}$  alkenyl group, a branched  $C_{5-10}$  alkynyl group or a bridged cyclic hydrocarbon group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

3. The prostaglandin derivative of Formula (I) according to Claim 2 wherein X is a chlorine or bromine atom in the  $\alpha$ - or  $\beta$ -position,  $R^1$  is a  $C_{3-10}$  cycloalkyl group, a  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl group or a branched  $C_{5-10}$  alkenyl group, and  $R^2$  is a hydrogen atom or a  $C_{1-10}$  alkyl group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

4. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein is Y is a vinylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

5. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein is Y is an ethynylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

6. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 5 wherein is A is a group represented by the formula:



(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an

integer of 1 to 3, and r is 0 or 1); the pharmaceutically acceptable salt thereof or the hydrate thereof.

7. The prostaglandin derivative of Formula (I) according to Claim 6 wherein is p is 0; the pharmaceutically acceptable salt thereof or the hydrate thereof.

8. A pharmaceutical preparation which comprises as an effective ingredient the prostaglandin derivative according to any one of Claims 1 to 7, the pharmaceutically acceptable salt thereof or the hydrate thereof.